Two Sigma Investments LP lowered its position in Fresenius Medical Care (NYSE:FMS) by 34.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,898 shares of the company’s stock after selling 7,693 shares during the period. Two Sigma Investments LP’s holdings in Fresenius Medical Care were worth $783,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of FMS. Avestar Capital LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $115,000. SeaCrest Wealth Management LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $153,000. Millie Capital Management LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $203,000. HL Financial Services LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $215,000. Finally, Dean Capital Investments Management LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $259,000. Hedge funds and other institutional investors own 2.40% of the company’s stock.
A number of equities research analysts recently commented on the company. DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care in a research report on Thursday, April 5th. Zacks Investment Research upgraded Fresenius Medical Care from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Thursday, March 8th. Royal Bank of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care in a research report on Tuesday, February 27th. UBS raised Fresenius Medical Care from a “sell” rating to a “neutral” rating in a report on Thursday, January 4th. Finally, Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care in a report on Tuesday, January 2nd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $54.67.
Shares of NYSE:FMS opened at $52.36 on Wednesday. Fresenius Medical Care has a 12-month low of $42.59 and a 12-month high of $57.94. The company has a market capitalization of $31,337.78, a price-to-earnings ratio of 22.33 and a beta of 0.62. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.20 and a quick ratio of 0.96.
Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.08. Fresenius Medical Care had a return on equity of 11.64% and a net margin of 7.23%. The company had revenue of $5.22 billion during the quarter, compared to the consensus estimate of $5.37 billion. sell-side analysts anticipate that Fresenius Medical Care will post 2.9 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Fresenius Medical Care (NYSE:FMS) Shares Sold by Two Sigma Investments LP” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/04/18/two-sigma-investments-lp-sells-7693-shares-of-fresenius-medical-care-fms.html.
About Fresenius Medical Care
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.